Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test? [conferenceObject]
| dc.contributor.author | Alaşan, Fatih | |
| dc.contributor.author | Balbay, Ege Güleç | |
| dc.contributor.author | Cangür, Şengül | |
| dc.contributor.author | Balbay, Öner Abidin | |
| dc.contributor.author | Aydın, Leyla Yılmaz | |
| dc.contributor.author | Annakkaya, Ali Nihat | |
| dc.date.accessioned | 2020-04-30T23:31:57Z | |
| dc.date.available | 2020-04-30T23:31:57Z | |
| dc.date.issued | 2015 | |
| dc.department | DÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| dc.description | Annakkaya, Ali Nihat N/0000-0002-7661-8830 | en_US |
| dc.description | WOS: 000451979404055 | en_US |
| dc.description.abstract | … | en_US |
| dc.identifier.doi | 10.1183/13993003.congress-2015.PA2971 | |
| dc.identifier.issn | 0903-1936 | |
| dc.identifier.issn | 1399-3003 | |
| dc.identifier.uri | https://doi.org/10.1183/13993003.congress-2015.PA2971 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12684/4542 | |
| dc.identifier.volume | 46 | en_US |
| dc.identifier.wos | WOS:000451979404055 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | European Respiratory Soc Journals Ltd | en_US |
| dc.relation.ispartof | European Respiratory Journal | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Tuberculosis - management | en_US |
| dc.subject | Infections | en_US |
| dc.subject | Interstitial lung disease (connective tissue disease) | en_US |
| dc.title | Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test? [conferenceObject] | en_US |
| dc.type | Conference Object | en_US |
